Abstract | BACKGROUND: METHODS: Searches were performed in PubMed, EmBase, and the Cochrane Library to identify studies evaluating the association of EGFR mutation with OS in NSCLC patients through September 2017. RESULTS: 4373 NSCLC patients with brain metastases in 18 studies were involved. Mutated EGFR associated with significantly improved OS compared with wild type. Subgroup analyses suggested that this relationship persisted in studies conducted in Eastern, with retrospective design, with sample size ≥500, mean age of patients ≥65.0 years, percentage male < 50.0%, percentage of patients receiving tyrosine kinase inhibitor ≥30.0%. Finally, although significant publication bias was observed using the Egger test, the results were not changed after adjustment using the trim and fill method. CONCLUSIONS: This meta-analysis suggests that EGFR mutation is an important predictive factor linked to improved OS for NSCLC patients with brain metastases. It can serve as a useful index in the prognostic assessment of NSCLC patients with brain metastases.
|
Authors | Wen-Ya Li, Ting-Ting Zhao, Hui-Mian Xu, Zhen-Ning Wang, Ying-Ying Xu, Yunan Han, Yong-Xi Song, Jian-Hua Wu, Hao Xu, Song-Cheng Yin, Xing-Yu Liu, Zhi-Feng Miao |
Journal | BMC cancer
(BMC Cancer)
Vol. 19
Issue 1
Pg. 145
(Feb 13 2019)
ISSN: 1471-2407 [Electronic] England |
PMID | 30760227
(Publication Type: Journal Article, Meta-Analysis, Systematic Review)
|
Chemical References |
- Biomarkers, Tumor
- EGFR protein, human
- ErbB Receptors
|
Topics |
- Biomarkers, Tumor
(genetics)
- Brain Neoplasms
(diagnosis, genetics, secondary)
- Carcinoma, Non-Small-Cell Lung
(diagnosis, genetics, secondary)
- ErbB Receptors
(genetics)
- Humans
- Lung Neoplasms
(diagnosis, genetics, pathology)
- Mutation
(genetics)
- Prognosis
|